To investigate the synergistic therapeutic potential of combined angiotensin II receptor blocker and IGF-1 replacement in attenuating NASH-associated skeletal muscle atrophy. The gene discussed is IGF1; the disease is metabolic dysfunction-associated steatohepatitis.